Fernando Aranda

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6876155/publications.pdf

Version: 2024-02-01

63 papers	3,984 citations	172386 29 h-index	143943 57 g-index
64 all docs	64 docs citations	64 times ranked	8028 citing authors

#	Article	IF	Citations
1	Novel strategies exploiting interleukin-12 in cancer immunotherapy. , 2022, 239, 108189.		35
2	Revisiting Intracavitary Immunotherapy of Cancer. Clinical Cancer Research, 2022, 28, 1993-1995.	3.2	0
3	Overcoming the limitations of cytokines to improve cancer therapy. International Review of Cell and Molecular Biology, 2022, , 107-141.	1.6	7
4	Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution. Prostate, 2022, 82, 1331-1337.	1.2	2
5	Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis. OncoImmunology, 2022, 11, .	2.1	3
6	Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications. Cancers, 2021, 13, 963.	1.7	12
7	Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. , 2021, 9, e001587.		10
8	Firefighters for the Wrong Type of Inflammation in Tumors. Cancer Discovery, 2021, 11, 2372-2374.	7.7	3
9	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. , 2021, 9, e002953.		23
10	Production and use of adeno-associated virus vectors as tools for cancer immunotherapy. Methods in Enzymology, 2020, 635, 185-203.	0.4	3
11	Transforming growth factor beta (TGF-Î²) activity in immuno-oncology studies. Methods in Enzymology, 2020, 636, 129-172.	0.4	3
12	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature Communications, 2020, 11, 3819.	5.8	71
13	CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1074-1083.	1.3	14
14	Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic Agents. Cells, 2020, 9, 2589.	1.8	12
15	Multifaceted effects of soluble human CD6 in experimental cancer models. , 2020, 8, e000172.		7
16	Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity. Frontiers in Immunology, 2020, 11, 620283.	2.2	2
17	Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity. Cell Metabolism, 2019, 30, 754-767.e9.	7.2	67
18	Transgenic Tumor Models for Evaluating CAR Tâ€Cell Immunotherapies. Current Protocols in Pharmacology, 2019, 86, e66.	4.0	0

#	Article	IF	Citations
19	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-Î±. Journal of Immunology, 2019, 203, 696-704.	0.4	6
20	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. OncoImmunology, 2018, 7, e1433982.	2.1	38
21	Gut microbiota metabolites for sweetening type I diabetes. Cellular and Molecular Immunology, 2018, 15, 92-95.	4.8	9
22	Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis. Cellular and Molecular Immunology, 2018, 15, 898-906.	4.8	17
23	Immune effectors responsible for the elimination of hyperploid cancer cells. OncoImmunology, 2018, 7, e1463947.	2.1	14
24	Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SRâ€B1. European Journal of Immunology, 2017, 47, 1108-1118.	1.6	23
25	Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	10
26	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	2.1	62
27	Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance. Frontiers in Immunology, 2017, 8, 594.	2.2	12
28	Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model. Oncotarget, 2017, 8, 5247-5255.	0.8	10
29	Immunomodulatory effects of soluble CD5 on experimental tumor models. Oncotarget, 2017, 8, 108156-108169.	0.8	8
30	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell, 2016, 30, 147-160.	7.7	410
31	Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival. International Journal of Cancer, 2016, 139, 1297-1302.	2.3	14
32	CD6 modulates thymocyte selection and peripheral T cell homeostasis. Journal of Experimental Medicine, 2016, 213, 1387-1397.	4.2	68
33	Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function. OncoImmunology, 2016, 5, e1196309.	2.1	10
34	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology, 2016, 5, e1214790.	2.1	64
35	Trial Watchâ€”Immunostimulation with cytokines in cancer therapy. OncoImmunology, 2016, 5, e1115942.	2.1	52
36	Trial Watchâ€”Oncolytic viruses and cancer therapy. OncoImmunology, 2016, 5, e1117740.	2.1	88

#	Article	IF	Citations
37	Trial Watchâ€"Small molecules targeting the immunological tumor microenvironment for cancer therapy. OncoImmunology, 2016, 5, e1149674.	2.1	46
38	Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination. OncoImmunology, 2016, 5, e1075113.	2.1	20
39	CD5 as a Target for Immune-Based Therapies. Critical Reviews in Immunology, 2015, 35, 85-115.	1.0	20
40	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology, 2015, 4, e1008814.	2.1	102
41	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology, 2015, 4, e1008866.	2.1	237
42	Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. Journal of Hepatology, 2015, 63, 329-336.	1.8	21
43	Trial Watch: Adoptive cell transfer for oncological indications. OncoImmunology, 2015, 4, e1046673.	2.1	29
44	Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology, 2015, 4, e1026531.	2.1	26
45	Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene, 2015, 34, 3053-3062.	2.6	67
46	Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases. PLoS ONE, 2014, 9, e96799.	1.1	12
47	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
48	Trial watch. OncoImmunology, 2014, 3, e29030.	2.1	51
49	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	2.1	686
50	Trial Watch. OncoImmunology, 2014, 3, e29179.	2.1	76
51	Trial Watch. OncoImmunology, 2014, 3, e27048.	2.1	69
52	Trial watch: IDO inhibitors in cancer therapy. OncoImmunology, 2014, 3, e957994.	2.1	223
53	Trial Watch. OncoImmunology, 2014, 3, e27297.	2.1	99
54	Myeloid-derived cells are key targets of tumor immunotherapy. OncoImmunology, 2014, 3, e28398.	2.1	47

#	Article	IF	Citations
55	Trial watch: Dendritic cell-based anticancer therapy. OncoImmunology, 2014, 3, e963424.	2.1	62
56	Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. OncoImmunology, 2014, 3, e955685.	2.1	16
57	Trial Watch. OncoImmunology, 2014, 3, e27878.	2.1	134
58	Impact of myeloid cells on the efficacy of anticancer chemotherapy. Current Opinion in Immunology, 2014, 30, 24-31.	2.4	35
59	Trial Watch. OncoImmunology, 2014, 3, e28344.	2.1	31
60	Trial Watch. OncoImmunology, 2013, 2, e26621.	2.1	101
61	Induction of Monocyte Chemoattractant Protein-1 and Interleukin-10 by TGFÎ²1 in Melanoma Enhances Tumor Infiltration and Immunosuppression. Cancer Research, 2011, 71, 812-821.	0.4	65
62	Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors. Cancer Research, 2011, 71, 3214-3224.	0.4	63
63	Peptide inhibitors of transforming growth factorâ€Î²2 enhance the efficacy of antitumor immunotherapy. International Journal of Cancer, 2009, 125, 2614-2623.	2.3	62